Modified fragments from the octarepeat region of prion protein as hemin binders
View Patent ↗An example of the composition incudes at least one amino acid sequence from the octarepeat region of hemin that is modified by substituting at least one proline (P) residue in the amino acid sequence. The composition is effective to bind with hemin and for treating hemorrhagic injury.
1. A composition comprising at least one isolated amino acid sequence selected from SEQ ID NOs: 2, 3, 4, 5, and 6 in which at least one proline (P) residue in the amino acid sequence is substituted by an amino acid having the formula
wherein R1 is a methyl group and R2 is an alkyl functional group having 1 to 4 carbon atoms.
2. The composition of claim 1 , wherein R2 is selected from a methyl, ethyl, butyl, and propyl group.
3. The composition of claim 1 , wherein R2 is a methyl group.
4. The composition of claim 1 , wherein the composition is within a pharmaceutical dosage form.
5. A method of binding hemin, the method comprising administering to a hemin solution a composition comprising at least one isolated amino acid sequence selected from SEQ ID NOs: 2, 3, 4, 5, and 6 in which at least one proline (P) residue in the amino acid sequence is substituted by an amino acid having the formula
wherein R1 is a methyl group and R2 is an alkyl functional group having 1 to 4 carbon atoms; and
wherein the isolated amino acid sequence is effective for binding to hemin in the hemin solution.
6. The method of claim 5 , wherein R2 is selected from a methyl, ethyl, butyl, and propyl group.
7. The method of claim 5 , wherein R2 is a methyl group.
8. The method of claim 5 , wherein the composition is within a pharmaceutical dosage form.
9. A method of treating a hemorrhagic injury, the method comprising administering to a patient in need thereof a therapeutically effective composition comprising at least one isolated amino acid sequence selected from SEQ ID NOs: 2, 3, 4, 5, and 6 in which at least one proline (P) residue in the amino acid sequence is substituted by an amino acid having the formula
wherein R1 is a methyl group and R2 is an alkyl functional group having 1 to 4 carbon atoms.
10. The method of claim 9 , wherein R2 is selected from a methyl, ethyl, butyl, and propyl group.
11. The method of claim 9 , wherein R2 is a methyl group.
12. The method of claim 9 , wherein the composition is within a pharmaceutical dosage form.
13. The method of claim 9 , wherein the hemorrhagic injury is at least one hemorrhagic injury selected from the group consisting of stroke and traumatic brain injury.